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and cost savings. Further research is needed to determine the cost-effectiveness 
of ATO+ATRA.
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Objectives: The aim of this study was to compare the costs of disease management 
based on revised diagnoses after centralized histological reviews for sarcoma, GIST, 
and desmoid tumors with the costs based on diagnoses before reviews. MethOds: 
A decision tree was constructed. For both options, the initial pathway was the World 
Health Organization (WHO) Classification of soft tissue and bone tumors. Diagnoses 
were considered concordant only when the final diagnosis was categorized in the 
same manner as the initial finding, as defined by the WHO classification. The deci-
sion tree was evaluated over a time horizon of 12 months. Disease management and 
the probabilities were based on a cohort of patients who had a histological review 
performed within the RRePS (Réseau de Référence en Pathologie des Sarcomes) 
network in 2010. The characteristics of the patient and disease, as well as any rel-
evant guidelines, were used. All of the disease managements were defined by the 
authors of this study. The costs were considered from the French National Health 
Insurance (NHI) perspective and the costs of the histological review were extracted 
from the literature. The costs were assessed for each pathway and expressed in 
Euros 2013. The expected costs were calculated. One-way and probabilistic sensitiv-
ity analyses were performed. Results: A total of 2,425 patients underwent a histo-
logical review. Of these, 341 patients were found to have a discordant diagnosis. Ten 
patients were excluded due to missing data. The costs reached € 8,420 (histological 
review included) when disease management was based on revised diagnoses and 
€ 8,610 when not. cOnclusiOns: In addition to the positive impact of centralized 
histological reviews on the quality of diagnosis for sarcoma, GIST, and desmoid 
tumors, our model demonstrated that histological reviews lower the cost of disease 
management for the French NHI.
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Objectives: A cost analysis investigating TomoTherapy® (Accuray), Elekta 
Volumetric-modulated Arc Therapy (VMAT®) and Varian RapidArc®was conducted 
in patients with head and neck cancer. MethOds: The cost-analysis, funded by 
the National Institute of Cancer (INCa), was performed prospectively based on 
a multicenter study. Cost calculations were strictly based on a micro costing 
approach according to the hospitals’ point of view. Only resources which are likely 
to vary between the strategies being compared were considered. Data on consump-
tion of resources were collected from the treatment planning until the end of the 
last irradiation session. Productivity losses of radiotherapy involved personnel 
related to organisational constraints or absenteeism, costs of administrative per-
sonnel, costs of logistics and general management were not taken into account. 
All costs were given in 2013 euros. Numbers of irradiation sessions were compared 
using Kruskal-Wallis test. Uncertainty was captured by one-way and probabilis-
tic sensitivity analyses using a non-parametric bootstrap method. Results: 174 
patients were enrolled in 16 French centers from February 2010 to February 2012. 
173 economic questionnaires were exploitable. The mean numbers of sessions 
were 34.33 (SD: 2.90) for TomoTherapy® (n= 73) and 34.53 (SD: 2.57) for Varian 
RapidArc® (n= 92, p= 0.603). Eight patients were treated with Elekta Volumetric-
modulated Arc Therapy (VMAT®). For irradiation (all sessions included), the over 
cost of TomoTherapy® (n= 73) reached € 1,109 per patient compared to Varian 
RapidArc® (n= 92). Sensitivity analyses showed that the annual operating time of 
the accelerators played a major role in irradiation costs. cOnclusiOns: This is 
to our knowledge the first study highlighting costs incurred by different Intensity-
Modulated ArcTherapy (IMAT) modalities in this setting. Costs of TomoTherapy® 
appeared more expensive than RapidArc®. The study should be now completed 
by a cost-effectiveness analysis in order to shed further light on which modality 
to focus on.
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Objectives: Diffuse large B-cell lymphoma (DLBCL) is the most common type of 
non-Hodgkin lymphoma and treatment is usually given with curative intent. Using 
restricted datasets derived from clinical trials, previous studies examining the cost 
of treating this cancer have generally focussed on first-line therapy alone; meaning 
of progression-free survival (PFS) curves for dabrafenib and vemurafenib, from their 
respective clinical trials with dacarbazine as a common comparator. The model 
was applied to the conditions of locally-specific population data and treatment 
costs, including adverse events, of patients with MMM. In the model, individuals 
moved from progression-free state to post-progression state or death and were 
followed for 45 weeks. We compared vemurafenib and dabrafenib from the payers’ 
perspective at the price level determined by international reference pricing as of 
December 2013 in terms of costs and progression-free life years (PFLYs). Based on 
the cost-effectiveness model, we carried out budget impact analysis for a scenario 
with vemurafenib only and a scenario with vemurafenib and dabrafenib using their 
projected market shares. Results: Our model has shown that more than 99% of 
total treatment costs of MMM patients in Slovenia were due to drug costs of BRAF 
inhibitors in spite of the fact that treatment of associated adverse events were 5 
times higher in vemurafenib than in dabrafenib, primarily due to higher incidence 
of cutaneous squamous cell carcinoma and keratocanthoma. Treatment with dab-
rafenib vs. vemurafenib allowed to save € 13,009 and gain 0.022 PFLY at a discount 
rate of 3.5%; the sensitivity analysis showed robustness of findings and retained 
dominance of dabrafenib over vemurafenib. Budget impact analysis for a 3-year 
period revealed that introduction of dabrafenib would save the national Sick Fund 
€ 402,000 (€ 5,318,000 in the scenario without dabrafenib vs. € 4,916,000 in the sce-
nario with dabrafenib). cOnclusiOns: Study results suggest that introduction of 
dabrafenib in Slovenia could reduce costs and improve outcomes in MMM.
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Objectives: Multidisciplinary return-to-work (RTW) interventions effectively sup-
port cancer survivors to resume work and potentially increase quality of life, but 
are not or only partly reimbursed by health insurers. To ensure optimal support for 
cancer patients in resuming work, it is essential that hospitals can offer RTW in a 
financially viable way. We analysed the budget impact of a RTW intervention (coun-
selling by occupational physicians + physical exercise) and explored how financing 
of a return-to-work intervention can be arranged. MethOds: The budget impact 
analysis compared costs of RTW support for all patients able and willing to resume 
work versus no standardised support, for a large cancer centre serving a popula-
tion of 1 million inhabitants. Costs and financial benefits relevant from a societal 
perspective were considered, including intervention costs, productivity losses, and 
patients´ costs. We identified which stakeholders, including hospitals, employers, 
health insurances, social security, and patients accrue what costs; and which enjoy 
the financial benefits under different financing arrangements. Results: RTW costs 
are ≈ € 2,000 per patient. For a large cancer centre, the annual budget impact is € 817k 
in 2014, rising to € 14.7m in 2017. Ccosts for patients with a multidisciplinary rehabil-
itation need are typically covered by health insurance, leaving € 735k to be financed 
by the cancer centre. Small improvements in return-to-work and quality of life led 
to substantial reductions in productivity loss and future health care costs. These 
savings outweigh the costs of the intervention, rendering RTW cost-saving from a 
societal perspective. cOnclusiOns: From a societal perspective return-to-work is 
expected to be cost-saving. Hospitals bear the largest share of the cost, while most 
financial benefits fall upon other stakeholders. Re-distributing costs and financial 
benefits among stakeholders would result in feasible financing of the intervention.
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Objectives: To estimate the total costs of arsenic trioxide and all-trans retinoic 
acid (ATO+ATRA) versus ATRA and idarubicin (AIDA) regimens in Italy when used 
in 1st-line APL treatment. ATO+ATRA is approved in 2st-line treatment, but com-
monly used globally in 1st-line. MethOds: A Markov model was developed with 
three health states: non-progressive disease, progressive disease and death. Each 
month, patients could move from non-progressive to progressive disease or die 
from either state. After progression, patients discontinued treatment and switched 
to the other regimen. Treatment regimens, efficacy and adverse events were derived 
from published sources and expert opinion, while each arm’s unit costs (induc-
tion and consolidation for both; maintenance for AIDA only) were collected from 
standard Italian sources. Per-patient costs were reported, and extensive one-way 
sensitivity analyses were conducted. Results: Expected 2-year pharmacy costs 
for ATO+ATRA were € 46,600 versus € 5,300 for AIDA. However, direct medical (DM) 
costs (e.g., monitoring, hospitalizations, etc.) for ATO+ATRA were € 11,300 versus 
€ 28,500 for AIDA. The higher costs stemmed from AIDA consolidation taking place in 
a hospital setting and 2-year maintenance monitoring costs. The treatment failure 
likelihood for patients on AIDA was 14% versus 3% on ATO+ATRA. As these patients 
switched to 2nd-line treatment, relapse costs for AIDA were € 1,500 compared to € 400 
for ATO+ATRA. AIDA patients incurred higher costs from adverse events (AEs) than 
ATO+ATRA (€ 600 vs. € 300, respectively). Results were most sensitive to consolida-
tion cost changes: ATO+ATRA pharmacy costs and AIDA DM costs. cOnclusiOns: 
The results suggest potential cost savings due to DM, progression and AE costs 
for ATO+ATRA, although AIDA pharmacy costs are lower. Additionally, ATO+ATRA 
patients have lower clinical AE risks and shorter treatment duration (8 months 
versus 28 months for AIDA), which could lead to patients’ improved quality of life 
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Objectives: Venous thromboembolism (VTE) is a common complication for can-
cer patients, leading to hospitalizations that increase the cost of management of 
these patients. The objective of the present study was to evaluate the number and 
the cost of VTE-related hospitalizations for patients with breast or prostate cancer 
during the two first years of their oncologic treatment. MethOds: Patients with 
breast cancer (BC) or prostate cancer (PC) diagnosed in 2010 who had at least one 
VTE-related hospitalization during the following two years were selected from the 
French national hospital database (PMSI), using the disease-specific ICD-10 codes. 
Hospital costs were estimated from the third-party payer perspective using the 
official diagnosis related group (DRG) tariffs for each year considered. Results: In 
2010,62,365 patients newly diagnosed with BC and 45,551 with PC were admitted 
in French hospitals. Among them, 1,271 in the BC cohort (2.0%) and 997 in the PC 
cohort (2.2%) were hospitalized for VTE at least once during the two-year follow-
up, leading to 1,604 stays for BC patients and 1,210 stays for PC patients. During a 
2-years follow-up, 15.9% of BC patients and 14.4% of PC patients were re-hospitalized 
for VTE recurrence. The mean cost per stay was 3,261€ and 3,584€ for BC and PC 
respectively. Mean cost per patient was estimated at 3,302€ and 3,611€ for BC and 
PC patients hospitalized once for VTE-related events, and it increased to 5,545€ and 
5,692€ for BC and PC patients who presented recurrences. Over a 2-year period, total 
hospital cost induced by VTE-related events reached 1.98 million and 1.43 million € 
for BC and PC, respectively. cOnclusiOns: VTE-related hospitalizations in breast 
or prostate cancer patients lead to a significant economic burden that could be 
reduced by decreasing VTE recurrence.
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Objectives: To examine the economic burden and health care utilization of 
melanoma patients in the U. S. Medicare population. MethOds: A retrospec-
tive database analysis was performed using U. S. national Medicare claims from 
01JAN2008 to 31DEC2012. Melanoma patients were identified using International 
Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) diagnosis 
code 172. xx. The first diagnosis date was designated as the index date. A compara-
tor group was created, consisting of patients with the same age, region, gender, 
index year, and matched baseline Charlson Comorbidity Index scores but with-
out a melanoma diagnosis. A random index date was chosen for the comparator 
cohort to reduce selection bias. Patients were required to have continuous medical 
and pharmacy benefits 1 year pre- and post-index date. One-to-one propensity 
score matching (PSM) was performed to compare follow-up health care costs and 
utilizations between the cohorts, adjusting for demographic and clinical charac-
teristics. Results: Eligible patients (N= 12,762) were identified for the melanoma 
and comparison cohorts. After 1: 1 PSM, a total of 8,015 patients were matched 
from each cohort and baseline characteristics were well-balanced. More melanoma 
patients had health care utilizations, including Medicare carrier (99.6% vs. 64.3%), 
Durable Medical Equipment (DME; 19.8% vs. 14.4%) and Home Health Agency 
(HHA; 6.7% vs. 4.1%) claims, outpatient visits (68.4% vs. 35.4%), inpatient (10.9% 
vs. 6.6%) and skilled nursing facility (SNF) stays (2.4% vs. 1.7%), but fewer mela-
noma patients had prescription clams (43.6% vs. 49.8%). Patients diagnosed with 
melanoma incurred higher expenditures, including carrier ($3,527 vs. $1,324), DME 
($153 vs. $101), HHA ($325 vs. $203), outpatient ($8,816 vs. $3,151), inpatient ($1,725 
vs. $1,154) and total health care costs ($15,692 vs. $6,990) (p< 0.0001). Similar SNF, 
hospice and pharmacy claim costs were observed in both cohorts. cOnclusiOns: 
Patients diagnosed with melanoma had a higher burden of illness compared to 
the comparison cohort of non-melanoma patients.
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Objectives: The objective of this cost study was to measure the resource utilisa-
tion and direct costs associated with health care management of cervical abnormal 
cytology and cervical cancer in Slovakia and to provide a basis for cost-effective-
ness evaluations. MethOds: The cross-sectional survey was performed to obtain 
the information on the management of patients with cervical lesions (Low Grade 
Squamous Intraepithelial Lesion (LSIL), High Grade Squamous Intraepithelial Lesion 
(HSIL), Atypical Squamous Cells of Undetermined Significance (ASCUS), Cervical 
Intraepithelial Neoplasia (CIN) I-III) and cervical cancer (clinical stages IA1 to IVB) 
and to estimate the direct costs of the disease management. All types of health care 
used in the management of cervical lesions/cancer were evaluated (diagnostics, 
treatment and follow-up). Average costs per patient were assessed on a yearly basis 
and correspond to the prices in 2013. Results: Concerning the cervical lesions, the 
highest mean annual costs were identified in the CIN III (36.45%; € 1406.62), followed 
by CIN II (27.0%; € 1041.97), the most costly part of health care management being 
the treatment of lesions. The costs of health care management of cervical cancer 
depended on the clinical stage and the frequency of examinations during the year. 
The highest total costs (follow-up included) were identified in the stage III (19.33%; 
€ 4633.35) and IVB (14.24%; € 3413.22). However, the highest mean annual costs of 
diagnostics were determined in stage IB (15.39%; € 542.12), IIA (15.46%; € 544.33), 
IVA and IVB (14.89%; € 524.33). The most expensive treatment (including surgery, 
radiotherapy, concomitant chemoradiotherapy and palliative chemotherapy) was 
identified in the stage IIB (20.89%; € 3616.38) and III (21.01%; € 3637.79). In the most 
advanced stages IVA and IVB, the treatment expenses were lower. Follow-up man-
agement was the most expensive in the stage IVB (15%; € 531.66). cOnclusiOns: 
that their findings can neither be extrapolated to the general patient population 
nor to other points along the pathway. Based on empirical data from a representa-
tive population-based patient cohort, the objective of this study was to develop 
a simulation model that could predict costs at an individual level and estimate 
the real medical costs of treating DLBCL. MethOds: All patients newly diagnosed 
with DLBCL in the UK’s population-based Haematological Malignancy Research 
Network (www.hmrn.org) in 2007 were followed until 2013 (n= 271). The mapped 
treatment pathways, alongside cost information derived from the National Tariff 
2013/14, were incorporated into a patient level simulation model in order to reflect 
the heterogeneities of patient characteristics and treatment options. Results: 
The expected total medical costs were £23,184 for those treated curatively with 
chemotherapy and £2,125 for those with a palliative approach over a period of five 
years. The predicted medical cost of the first line was £15,243, and £16,325 and 
£7,145 for the second line and the third line treatments respectively. The predicted 
costs captured 94% of the actual costs and the proportion of patients simulated in 
each health state was identical to the empirical data, supporting the validity of the 
model. cOnclusiOns: This is the first cost modelling study to use empirical data 
to provide ‘real world’ evidence to estimate medical costs of entire DLBCL treatment 
pathways. Future application of the model developed here could be used to evaluate 
new technologies/treatments and support health care decision makers, especially 
in the era of personalised medicine.
PCN64
Cost-CoNsEquENCE aNalysis of aN aPrEPitaNt rEgimEN vErsus 
a staNdard aNtiEmEtiC rEgimEN for tHE PrEvENtioN of HigHly 
EmEtogENiC CHEmotHEraPy-iNduCEd NausEa aNd vomitiNg iN italy
Rosti G.1, Ravasio R.2
1ULSS 9 Treviso (Italy), Treviso, Italy, 2Health Publishing & Services, Milano, Italy
Objectives: Prevention of chemotherapy-induced nausea and vomiting (CINV) 
remains an important goal for patients receiving cytotoxic treatment. The objec-
tive of this study was to assess, from the Italian National Health Service payer 
perspective, the costs of an antiemetic regimen using aprepitant, a selective neu-
rokinin-1 receptor antagonist, for patients receiving highly emetogenic chemo-
therapy. MethOds: A decision-analytic model was developed to compare an 
aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard 
antiemetic regimen (ondansetron and dexamethasone) for expected costs after 
highly emetogenic chemotherapy. The model was populated with clinical results 
from patients with high-dose cisplatin treatment in a randomized trial of CINV 
preventative therapy. Only direct medical costs (pharmacological treatment and 
emesis) – Euro 2014 – were considered. Sensitivity and Threshold analyses on key 
clinical and economic parameters were performed. Results: Aprepitant regimen 
showed the lower expected treatment cost (aprepitant regimen: € 109.88; standard 
antiemetic regimen € 115.57). The drug acquisition cost of the aprepitant regimen 
(aprepitant regimen: € 86.16; standard antiemetic regimen € 79.37) was offset by 
reduced health care resource utilization costs for CINV (aprepitant regimen: € 23.72; 
standard antiemetic regimen: € 36.20). Sensitivity and Threshold analysis confirmed 
the base case results. cOnclusiOns: The results of this cost-consequence analysis 
suggest that, from the Italian National Health Service payer perspective, aprepi-
tant regimen is a cost-saving strategy compared with antiemetic regimen without 
aprepitant in the prevention of highly emetogenic chemotherapy-induced nausea 
and vomiting.
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Objectives: Evaluate and compare the cost of non-small cell lung cancer (NSCLC) 
treatment by different standards of treatment in Vietnam. MethOds: A tree-deci-
sion model has been developed to estimate the cost of NSCLC. The analysis has 
been conducted based on the perspective of health insurance companies, there-
fore only medical direct costs, including cost for drugs and medical services has 
been evaluated. The list of medical services and drugs was derived from NCCN 
Clinical Practice Guidelines in Oncology (NCCN therapy) and Lung Cancer Therapy 
of Vietnam National Cancer Hospital (Vietnam therapy). The transition rates in the 
model were derived from clinical researches and consultation with experts. The 
cost of drugs and medical services has been averaged from the relevant medical 
services of some major hospitals in Vietnam. Results: The total treatment costs 
increase following the severity of stage whether treatment was implemented by 
Vietnamese or European standards. Moreover, in all stages of disease, the total 
treatment costs of NSCLC by Vietnamese guideline are less than that by NCCN 
standard (74,425,114 vs 79,729,000 in phase I; 139,031,940 vs 210,585,139 in phase II, 
172,333,617 vs 339,542,672 VND in phase III, and 160,690,121 VND vs 266,197,825 VND 
in phase IV, respectively). This can be explained by the lack of some expensive drugs 
and medical services in Vietnam due to the socio-economic conditions of Vietnam. 
In the structure of costs, cost for drugs take the dominant part with approximately 
76.61% by NCCN standard and 74.92% by Vietnamese standard, which is almost 3 
times higher than that of medical services. cOnclusiOns: The high cost of NCSLC 
should be considered to conduct the relevant health care policies, especially with 
high-cost drugs in late stages of disease. The cost of NSCLC treatment by NCCN 
therapy is higher than the cost of NSCLC treatment by Vietnam therapy.
PCN66
HosPital Cost of tHromBoEmBoliC EvENts iN BrEast or ProstatE 
CaNCEr PatiENts
Scotte F.1, Martelli N.1, Vainchtock A.2, Borget I.3
1Hopital Européen Georges Européen, Paris, France, 2HEVA, Lyon, France, 3Institut Gustave Roussy, 
Villejuif, France
